Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations and analyst consensus. We help you understand fair value estimates and potential upside or downside scenarios for any stock you are considering. Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections based on Wall Street research.
Leading global genomics technology provider Illumina Inc. (NASDAQ: ILMN) released first-quarter calendar 2026 financial results on May 3, 2026, that exceeded consensus analyst estimates across core metrics, including revenue, adjusted operating income, and adjusted earnings per share (EPS). The comp
Illumina Inc. (ILMN) Posts Robust Q1 2026 Earnings Beat Driven by Clinical Sequencing Strength and Surging NovaSeq X Demand - Options Activity
ILMN - Stock Analysis
4259 Comments
1702 Likes
1
Saija
Regular Reader
2 hours ago
Every aspect is handled superbly.
👍 280
Reply
2
Santhiago
Elite Member
5 hours ago
Recent market gains appear to be driven by sector rotation.
👍 215
Reply
3
Meganmarie
Elite Member
1 day ago
Investor sentiment is constructive, with broad participation across sectors. Minor pullbacks are natural following consecutive rallies but do not indicate a change in the overall trend. Analysts highlight that support zones are holding firm.
👍 39
Reply
4
Chealsey
New Visitor
1 day ago
This would’ve helped me make a better decision.
👍 156
Reply
5
Leily
Returning User
2 days ago
Who else is on the same wavelength?
👍 289
Reply
© 2026 Market Analysis. All data is for informational purposes only.